Page 94 - Cigna News Today

(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danugl...

Eli Lilly's drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues. 

Global bank executives said that dealmaking conditions have begun to improve, with some predicting a better outlook for strategic mergers and acquisitions at an industry event Tuesday. Both M&A activity and initial public offerings (IPOs) faltered last year after Russia's invasion of Ukraine and the U.S. Federal Reserve's aggressive rate hikes to tame inflation. "The M&A deals are coming a little faster," Bank of America CEO Brian Moynihan told the Goldman Sachs U...

Because social connection is such a significant predictor of longevity, it's adults who need more playdates.

Because social connection is such a significant predictor of longevity, it's adults who need more playdates.

Because social connection is such a significant predictor of longevity, it's adults who need more playdates.

Because social connection is such a significant predictor of longevity, it's adults who need more playdates.

By Saeed Azhar and Tatiana Bautzer NEW YORK (Reuters) - Global bank executives said that dealmaking conditions have begun to improve, with some predic...

Because social connection is such a significant predictor of longevity, it's adults who need more playdates.

Because social connection is such a significant predictor of longevity, it's adults who need more playdates.